Search

Displaying results 2021 - 2030 of 10000 in total
  1. Drug

    Flufenamic acid

    go.drugbank.com/drugs/DB02266
    Approved

    (From Martindale, The Extra Pharmacopoeia, 30th ed, p16) … An anthranilic acid derivative with analgesic, anti-inflammatory, and antipyretic properties. It is used in musculoskeletal and joint disorders and administered by mouth and topically.

  2. Drug

    Dehydrocholic acid

    go.drugbank.com/drugs/DB11622
    Approved

    It has been used for stimulation of biliary lipid secretion. The use of dehydrocholic acid in over-the-counter products has been discontinued by Health Canada.

    Mixtures: Duchol Ect
  3. Drug

    Evinacumab

    go.drugbank.com/drugs/DB15354
    ApprovedInvestigational

    [A229278] In February 2021, evinacumab became the first-and-only inhibitor of ANGPTL3 to receive FDA approval after it was granted approval for the adjunctive treatment of homozygous familial hypercholesterolemia … cardiovascular risk, and it was these observations that provided a rationale for the development of a therapy targeted against ANGPTL3.

  4. Drug

    Plasma protein fraction (human)

    go.drugbank.com/drugs/DB13968
    ApprovedInvestigational

    [L2262] The proteins in PPFh are stabilized with sodium caprylate and acetyltryptophan and it contains some electrolytes such as sodium, potassium and chloride.[L2261] … [A32512] It is already reviewed under the category of biologics by the FDA where the processing, required tests, requirements and labeling are incorporated.

  5. Drug

    Fenoldopam

    go.drugbank.com/drugs/DB00800
    Approved

    A dopamine D1 receptor agonist that is used as an antihypertensive agent. It lowers blood pressure through arteriolar vasodilation.

  6. Drug

    Levothyroxine

    go.drugbank.com/drugs/DB00451
    ApprovedInvestigational

    [F4633] T<sub>4</sub> and T<sub>3</sub> act on nearly every cell of the body, but have a particularly strong effect on the cardiac system. … sub>4</sub> (tetraiodothyronine or thyroxine) and T<sub>3</sub> (triiodothyronine or [DB00279]), resulting in diminished down-stream effects of these hormones.

    Products: Levo-T, Levo-T 50mcg - Tab
  7. Drug

    Oxytetracycline

    go.drugbank.com/drugs/DB00595
    ApprovedInvestigationalVet approved

    A tetracycline analog isolated from the actinomycete streptomyces rimosus and used in a wide variety of clinical conditions.

    Mixtures: HEKSA 30 MG/G + 10000 I.U./G MERHEMProducts: TERRAMICINA 125 MG, TERRAFUNGIN 100 MG/2 ML AMPUL, 1 ADET
  8. Drug

    Pirtobrutinib

    go.drugbank.com/drugs/DB17472
    ApprovedInvestigational

    [A256788] In January 2023, the use of pirtobrutinib for the treatment of relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy was approved under the FDA's Accelerated … Although the mechanisms of resistance to covalent BTK inhibitors have not been fully elucidated, it appears that the presence of Cys481 mutations is the most common reason for resistance to covalent BTK

  9. Drug

    Avalglucosidase alfa

    go.drugbank.com/drugs/DB16099
    ApprovedInvestigational

    GAA is an essential enzyme that hydrolyzes glycogen into free glucose for use in cellular functions. … [A232955] In clinical trials, avalglucosidase alfa improved lung function in patients with Pompe disease.

  10. Drug

    Trimethobenzamide

    go.drugbank.com/drugs/DB00662
    ApprovedInvestigational

    Trimethobenzamide is a novel antiemetic which prevents nausea and vomiting in humans. Its actions are unclear but most likely involves the chemoreceptor trigger zone (CTZ). … In dogs pretreated with trimethobenzamide HCl, the emetic response to apomorphine is inhibited, while little or no protection is afforded against emesis induced by intragastric copper sulfate.

    Mixtures: EMEDUR 100 MG/20 MG SUPOZİTUAR, 5 ADET, EMEDUR 200 MG SUPOZITUAR, 100 ADETSynonyms: N-[[4-(2-dimethylaminoethoxy)phenyl]methyl]-3,4,5-trimethoxybenzamide